A detailed history of Persistent Asset Partners LTD transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Persistent Asset Partners LTD holds 42,645 shares of CTMX stock, worth $164,609. This represents 0.09% of its overall portfolio holdings.

Number of Shares
42,645
Holding current value
$164,609
% of portfolio
0.09%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 10, 2025

BUY
$1.76 - $3.23 $75,055 - $137,743
42,645 New
42,645 $136 Million

Others Institutions Holding CTMX

About CytomX Therapeutics, Inc.


  • Ticker CTMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,950,200
  • Market Cap $255M
  • Description
  • CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...
More about CTMX
Track This Portfolio

Track Persistent Asset Partners LTD Portfolio

Follow Persistent Asset Partners LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Persistent Asset Partners LTD, based on Form 13F filings with the SEC.

News

Stay updated on Persistent Asset Partners LTD with notifications on news.